Grunberger Diabetes Institute, Department of Internal Medicine, Center for Molecular Medicine & Genetics, Wayne State University School of Medicine, Bloomfield Hills, MI 48302, USA.
Diabetes Obes Metab. 2013 Mar;15 Suppl 1:1-5. doi: 10.1111/dom.12061.
Insulin replacement therapy corrects a core defect of diabetes pathophysiology. Since its introduction as a therapeutic modality almost 100 years ago, insulin therapy has undergone remarkable changes in purity and ability to provide more physiologic control of blood glucose levels. With glucose-lowering potential limited only by risks of hypoglycaemia, which remains the major limitation in our ability to achieve glycaemic goals, insulin replacement therapy remains a cornerstone of therapy. Major progress in reducing the risks of hypoglycemia has occurred with the development of insulin analogs. This review article briefly chronicles the evolution of insulin replacement strategies, highlighting both challenges in pharmaceutical development and patient acceptance, underscoring achievements, as well as denoting what improvements are still needed.
胰岛素替代疗法纠正了糖尿病病理生理学的一个核心缺陷。自近 100 年前作为一种治疗方式引入以来,胰岛素治疗在纯度和提供更生理性的血糖水平控制方面发生了显著变化。由于低血糖的风险限制了降糖的潜力,而低血糖仍然是我们实现血糖目标的主要限制因素,胰岛素替代疗法仍然是治疗的基石。随着胰岛素类似物的发展,降低低血糖风险方面取得了重大进展。本文简要回顾了胰岛素替代策略的演变,重点介绍了药物开发和患者接受方面的挑战和成就,强调了仍需改进的地方。